News

First Patient Dosed in XLRP Treatment Trial

Applied Genetic Technologies Corporation has announced that the first patient was dosed in its Phase 1/2 clinical trial evaluating the safety and efficacy of AGTC-501 for the treatment of X-linked …

ReNeuron wins grant to advance development of stem cell therapy

UK-based developer of cell-based therapeutics, ReNeuron Group, has won a grant to advance the development of its hRPC stem cell therapy candidate for blindness-causing degenerative diseases of the retina. The …

Virgin Money London Marathon

The 2018 London Marathon was the 38th London Marathon race and it took place on Sunday, 22 April 2018, in London, England. RP Fighting Blindness was delighted to be part …

ProQR Usher clinical development programme

ProQR is a young biotech firm based in the Netherlands that is in the early stages of planning a number of clinical trials targeting vision loss in Usher 2A patients …

Statement from the Chairman

Important information about RP Fighting Blindness I have written to our members to ask for their assistance in an important matter, the re-naming of our wonderful charity. This was done …

V.I. Salsa Dance Classes for Beginners

We’ve been asked to share details of some exciting new classes, run by RPFB Ambassador Bhavini Makwana. Blind and partially sighted people can now learn Salsa dancing from London’s most …

The RP Fighting Blindness Working Age Group Project online forum

A call for participants to join our online forum The RP Fighting Blindness Working Age Group Project is a partnership project led by RP Fighting Blindness, with involvement from Thomas …

Gene Therapy Trials for Best Disease could start in two years

Scientists in the U.S. say human trials of gene therapy for the inherited form of blindness known as vitelliform macular degeneration, or Best disease, could be less than two years …

Immune cells in the retina can spontaneously regenerate

Immune cells called microglia can completely repopulate themselves in the retina after being nearly eliminated, according to a new study in mice from scientists at the National Eye Institute (NEI). …

Nightstar Therapeutics announces initiation of STAR Phase III Registrational Trial for NSR-REP1 in Choroideremia

Nightstar Therapeutics PLC, a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, has announced the initiation of the company’s STAR Phase III registrational trial to study the …

MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

MeiraGTx, a London and New York based gene therapy company, has announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to its gene therapy product candidate A002 …

How to Get Fit Fast

How to Get Fit Fast is a new Channel 4 series presented by Amar Latif, the blind entrepreneur and Founder and Director of Traveleyes, the world’s first tour operator offering worldwide …